A security alliance shaping the future of connected infrastructure

Tern plc

Device Authority’s KeyScaler platform has built its reputation on automating device identity at scale. Rather than relying on manual oversight, the system creates, rotates and retires digital identities across vast fleets of connected assets. For investors, the attraction is clear: this reduces exposure to breaches that often trace back to unmanaged or outdated credentials. But automation alone is only part of the equation. To be effective, these capabilities must be embedded into complex corporate ecosystems, which is where Optiv’s advisory strength comes into play.

The shift toward Zero Trust frameworks has sharpened the spotlight on machine identities. Unlike perimeter-based security, Zero Trust requires constant validation of every entity on the network. Device Authority’s identity-first approach fits directly into this narrative, while Optiv brings the experience needed to operationalise it for clients that span critical sectors such as energy, healthcare and manufacturing. The synergy points to a model where cyber defences are not bolted on as an afterthought but are woven into the operational fabric from the outset.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

AI search makes message measurement a healthcare priority

As AI changes search, healthcare companies need to know whether their messages are being seen, understood and represented correctly.

Search